Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
Corianò M, Giannarelli D, Scartabellati G, De Giorgi U, Brighi N, Fornarini G, Tommasi C, Giudice GC, Rebuzzi SE, Puglisi S, Caffo O, Kinspergher S, Mennitto A, Cattrini C, Santoni M, Verzoni E, Rametta A, Stellato M, Malgeri A, Roviello G, Brunelli M, Signori A, Banna GL, Buti S. Corianò M, et al. Among authors: puglisi s. Expert Rev Anticancer Ther. 2023 May;23(5):545-554. doi: 10.1080/14737140.2023.2200168. Epub 2023 Apr 10. Expert Rev Anticancer Ther. 2023. PMID: 37017710
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score.
Fornarini G, Rebuzzi SE, Buti S, Rescigno P, Merseburger A, Sternberg CN, de Giorgi U, Basso U, Maruzzo M, Giannatempo P, Ponzano M, Giunta EF, Catalano F, Murianni V, Damassi A, Cremante M, Gandini A, Puglisi S, Llaja Obispo MA, Signori A, Banna GL. Fornarini G, et al. Among authors: puglisi s. Minerva Urol Nephrol. 2023 Jun;75(3):308-318. doi: 10.23736/S2724-6051.22.05135-7. Epub 2022 Dec 13. Minerva Urol Nephrol. 2023. PMID: 36511379 Free article. Clinical Trial.
The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
Buti S, Tommasi C, Scartabellati G, De Giorgi U, Brighi N, Rebuzzi SE, Puglisi S, Caffo O, Kinspergher S, Mennitto A, Cattrini C, Santoni M, Verzoni E, Rametta A, Stellato M, Malgeri A, Roviello G, de Filippo M, Cortellini A, Bersanelli M. Buti S, et al. Among authors: puglisi s. Anticancer Drugs. 2023 Jan 1;34(1):178-186. doi: 10.1097/CAD.0000000000001356. Epub 2022 Oct 22. Anticancer Drugs. 2023. PMID: 36539370 Free PMC article.
Reliability of patient-reported toxicities during adjuvant chemotherapy.
Cremante M, Pastorino A, Ponzano M, Grassi M, Martelli V, Puccini A, Catalano F, Murianni V, Iaia ML, Puglisi S, Gandini A, Fornarini G, Caprioni F, Andretta V, Pessino A, Comandini D, Sciallero MS, Mammoliti S, Sormani MP, Sobrero A. Cremante M, et al. Among authors: puglisi s. Eur J Cancer. 2023 Mar;182:115-121. doi: 10.1016/j.ejca.2023.01.005. Epub 2023 Jan 14. Eur J Cancer. 2023. PMID: 36758476
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study.
Tommasi C, Scartabellati G, Giannarelli D, Giorgi U, Brighi N, Fornarini G, Rebuzzi SE, Puglisi S, Caffo O, Kinspergher S, Mennitto A, Cattrini C, Santoni M, Verzoni E, Rametta A, Stellato M, Malgeri A, Roviello G, Brunelli M, Buti S. Tommasi C, et al. Among authors: puglisi s. Ther Adv Urol. 2023 Jul 22;15:17562872231187216. doi: 10.1177/17562872231187216. eCollection 2023 Jan-Dec. Ther Adv Urol. 2023. PMID: 37492625 Free PMC article.
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score.
Mazzaschi G, Lazzarin A, Santoni M, Trentini F, Giorgi U, Brighi N, Tommasi C, Puglisi S, Caffo O, Kinspergher S, Mennitto A, Cattrini C, Verzoni E, Rametta A, Stellato M, Malgeri A, Roviello G, Silini EM, Rescigno P, Rebuzzi SE, Fornarini G, Quaini F, Giudice GC, Banna GL, Buti S. Mazzaschi G, et al. Among authors: puglisi s. Front Biosci (Elite Ed). 2023 Jul 28;15(3):20. doi: 10.31083/j.fbe1503020. Front Biosci (Elite Ed). 2023. PMID: 37743233 Free article.
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25).
Gambale E, Maruzzo M, Messina C, De Gennaro Aquino I, Vascotto IA, Rossi V, Bimbatti D, Cavasin N, Messina M, Mennitto A, Rebuzzi SE, Nasso C, Mercinelli C, Maiorano BA, Fanelli M, Sorarù M, Scolari F, Mela MM, Galli L, Salfi A, Rizzo M, Puglisi S, Orlando V, Fornarini G, Rametta A, Giannatempo P, Cerbone L, Doni L, Roviello G, Pillozzi S, Antonuzzo L. Gambale E, et al. Among authors: puglisi s. Clin Genitourin Cancer. 2024 Aug;22(4):102099. doi: 10.1016/j.clgc.2024.102099. Epub 2024 Apr 24. Clin Genitourin Cancer. 2024. PMID: 38776583 Free article.
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer.
Del Re M, Crucitta S, Brighi N, Kinspergher S, Mercinelli C, Rizzo M, Conteduca V, Rebuzzi SE, Beninato T, Venturi G, Doni L, Verzoni E, Puglisi S, Landriscina M, Porta C, Manfredi F, Caffo O, De Giorgi U, Fogli S, Danesi R. Del Re M, et al. Among authors: puglisi s. Clin Genitourin Cancer. 2024 Oct;22(5):102147. doi: 10.1016/j.clgc.2024.102147. Epub 2024 Jun 27. Clin Genitourin Cancer. 2024. PMID: 39030142
167 results